Medicare now covers a blood test for colon cancer screening: Do you still need colonoscopy?
Medicare’s June 2026 coverage decision gives eligible average-risk adults another colorectal cancer screening option: a blood-based test every three years. But if the result is positive, a follow-up colonoscopy is still needed, and major cancer guidance still prefers colonoscopy or stool-based tests over blood tests.
Medicare now covers certain blood-based tests for colorectal cancer screening. For many readers, the practical takeaway is simple: this adds another screening option for eligible average-risk adults, but it does not replace colonoscopy if the blood test is positive.
The change matters because colorectal cancer screening works best when people actually complete it. In June 2026, CMS finalized Medicare coverage for eligible non-invasive blood-based biomarker screening tests, and the American Cancer Society updated its guidance in May 2026 to include blood-based screening while still preferring other screening methods.
What changed in June 2026?
CMS now covers certain blood-based biomarker tests for colorectal cancer screening once every three years when specific conditions are met. The test must be FDA-authorized for colorectal cancer screening and used in settings that meet Medicare’s coverage rules.
Medicare’s patient-facing coverage page says this preventive benefit is generally covered without out-of-pocket cost when the clinician accepts assignment. Even so, the exact logistics can vary depending on how the test is ordered and billed.
Who qualifies?
The Medicare coverage is aimed at people ages 45 to 85 who are asymptomatic and at average risk for colorectal cancer. In practical terms, that means people without a personal history of colorectal cancer, adenomatous polyps, or inflammatory bowel disease, and without a family history tied to inherited colorectal cancer syndromes.
That does not mean everyone in that age range should use the same test. The CDC recommends routine screening starting at age 45, with continued screening to age 75 for many adults and individualized decisions after that. The American Cancer Society uses a similar framework for average-risk adults.
How do blood tests compare with stool tests and colonoscopy?
For average-risk adults, there is more than one way to screen for colorectal cancer. The CDC lists stool-based tests such as FIT and gFOBT, stool DNA testing, and colonoscopy as established options.
The American Cancer Society’s 2026 update says blood-based tests are included, but they are not preferred. The reason is performance: compared with stool tests and direct visual exams, blood tests are less likely to detect precancerous growths and the earliest stage of cancer.
That does not make the blood test useless. It means it may be a reasonable option for people who are more likely to complete a blood draw than a stool test or colonoscopy. In public-health terms, a less-sensitive test can still help if it reaches people who would otherwise not get screened at all.
If the blood test is positive, do you still need a colonoscopy?
Yes. Medicare says a follow-up colonoscopy is covered after a positive blood-based biomarker result, and the CDC says colonoscopy is needed to complete screening after an abnormal non-colonoscopy test.
This is the key point for readers to understand: a blood test can start the screening process, but it is not the final step if something abnormal turns up. If you would not be willing or able to follow through with colonoscopy after a positive result, it is worth discussing that before choosing the blood test.
When screening is not the right approach
Screening is for people without symptoms. If you have blood in or on the stool, a persistent change in bowel habits, ongoing abdominal pain, or unexplained weight loss, you should not treat that as routine screening territory. Those symptoms need medical evaluation.
The same is true if you have a personal history of polyps, colorectal cancer, Crohn’s disease, ulcerative colitis, or a strong family history. People at higher risk may need a different test or a different schedule.
What readers can do now
- Check your risk category. If you are average risk and have no symptoms, you may have more than one screening option.
- Ask about tradeoffs. A blood test may be easier to complete, but major guidance still prefers stool-based testing or colonoscopy.
- Ask what happens after a positive result. Make sure you understand how follow-up colonoscopy would be scheduled and covered.
- Confirm your coverage details. Medicare rules are national, but billing and logistics can still vary.
- Do not ignore symptoms. Screening rules are not the same as evaluation for bleeding, pain, or other warning signs.
The bottom line: Medicare’s June 2026 decision makes blood-based colorectal cancer screening more available for eligible adults. But colonoscopy remains central, both as a preferred screening option in major guidance and as the necessary next step if a blood test comes back positive.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
